Pharmacological characterization of novel small molecule agonists and antagonists for the orphan receptor GPR139

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Pharmacological characterization of novel small molecule agonists and antagonists for the orphan receptor GPR139. / Pallareti, Lisa; Rath, Tine F; Trapkov, Boris; Tsonkov, Tsonko; Nielsen, Anders Thorup; Harpsøe, Kasper; Gentry, Patrick R; Bräuner-Osborne, Hans; Gloriam, David E; Foster, Simon R.

In: European Journal of Pharmacology, Vol. 943, 175553, 2023.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Pallareti, L, Rath, TF, Trapkov, B, Tsonkov, T, Nielsen, AT, Harpsøe, K, Gentry, PR, Bräuner-Osborne, H, Gloriam, DE & Foster, SR 2023, 'Pharmacological characterization of novel small molecule agonists and antagonists for the orphan receptor GPR139', European Journal of Pharmacology, vol. 943, 175553. https://doi.org/10.1016/j.ejphar.2023.175553

APA

Pallareti, L., Rath, T. F., Trapkov, B., Tsonkov, T., Nielsen, A. T., Harpsøe, K., Gentry, P. R., Bräuner-Osborne, H., Gloriam, D. E., & Foster, S. R. (2023). Pharmacological characterization of novel small molecule agonists and antagonists for the orphan receptor GPR139. European Journal of Pharmacology, 943, [175553]. https://doi.org/10.1016/j.ejphar.2023.175553

Vancouver

Pallareti L, Rath TF, Trapkov B, Tsonkov T, Nielsen AT, Harpsøe K et al. Pharmacological characterization of novel small molecule agonists and antagonists for the orphan receptor GPR139. European Journal of Pharmacology. 2023;943. 175553. https://doi.org/10.1016/j.ejphar.2023.175553

Author

Pallareti, Lisa ; Rath, Tine F ; Trapkov, Boris ; Tsonkov, Tsonko ; Nielsen, Anders Thorup ; Harpsøe, Kasper ; Gentry, Patrick R ; Bräuner-Osborne, Hans ; Gloriam, David E ; Foster, Simon R. / Pharmacological characterization of novel small molecule agonists and antagonists for the orphan receptor GPR139. In: European Journal of Pharmacology. 2023 ; Vol. 943.

Bibtex

@article{badec937fbde472d9b415c7252923c41,
title = "Pharmacological characterization of novel small molecule agonists and antagonists for the orphan receptor GPR139",
abstract = "The orphan G protein-coupled receptor GPR139 is predominantly expressed in the central nervous system and has attracted considerable interest as a therapeutic target. However, the biological role of this receptor remains somewhat elusive, in part due to the lack of quality pharmacological tools to investigate GPR139 function. In an effort to understand GPR139 signaling and to identify improved compounds, in this study we performed virtual screening and analog searches, in combination with multiple pharmacological assays. We characterized GPR139-dependent signaling using previously published reference agonists in Ca 2+ mobilization and inositol monophosphate accumulation assays, as well as a novel real-time GPR139 internalization assay. For the four reference agonists tested, the rank order of potency was conserved across signaling and internalization assays: JNJ-63533054 > Compound 1a » Takeda > AC4 > DL43, consistent with previously reported values. We noted an increased efficacy of JNJ-63533054-mediated inositol monophosphate signaling and internalization, relative to Compound 1a. We then performed virtual screening for GPR139 agonist and antagonist compounds that were screened and validated in GPR139 functional assays. We identified four GPR139 agonists that were active in all assays, with similar or reduced potency relative to known compounds. Likewise, compound analogs selected based on GPR139 agonist and antagonist substructure searches behaved similarly to their parent compounds. Thus, we have characterized GPR139 signaling for multiple new ligands using G protein-dependent assays and a new real-time internalization assay. These data add to the GPR139 tool compound repertoire, which could be optimized in future medical chemistry campaigns. ",
author = "Lisa Pallareti and Rath, {Tine F} and Boris Trapkov and Tsonko Tsonkov and Nielsen, {Anders Thorup} and Kasper Harps{\o}e and Gentry, {Patrick R} and Hans Br{\"a}uner-Osborne and Gloriam, {David E} and Foster, {Simon R}",
note = "Copyright {\textcopyright} 2023. Published by Elsevier B.V.",
year = "2023",
doi = "10.1016/j.ejphar.2023.175553",
language = "English",
volume = "943",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Pharmacological characterization of novel small molecule agonists and antagonists for the orphan receptor GPR139

AU - Pallareti, Lisa

AU - Rath, Tine F

AU - Trapkov, Boris

AU - Tsonkov, Tsonko

AU - Nielsen, Anders Thorup

AU - Harpsøe, Kasper

AU - Gentry, Patrick R

AU - Bräuner-Osborne, Hans

AU - Gloriam, David E

AU - Foster, Simon R

N1 - Copyright © 2023. Published by Elsevier B.V.

PY - 2023

Y1 - 2023

N2 - The orphan G protein-coupled receptor GPR139 is predominantly expressed in the central nervous system and has attracted considerable interest as a therapeutic target. However, the biological role of this receptor remains somewhat elusive, in part due to the lack of quality pharmacological tools to investigate GPR139 function. In an effort to understand GPR139 signaling and to identify improved compounds, in this study we performed virtual screening and analog searches, in combination with multiple pharmacological assays. We characterized GPR139-dependent signaling using previously published reference agonists in Ca 2+ mobilization and inositol monophosphate accumulation assays, as well as a novel real-time GPR139 internalization assay. For the four reference agonists tested, the rank order of potency was conserved across signaling and internalization assays: JNJ-63533054 > Compound 1a » Takeda > AC4 > DL43, consistent with previously reported values. We noted an increased efficacy of JNJ-63533054-mediated inositol monophosphate signaling and internalization, relative to Compound 1a. We then performed virtual screening for GPR139 agonist and antagonist compounds that were screened and validated in GPR139 functional assays. We identified four GPR139 agonists that were active in all assays, with similar or reduced potency relative to known compounds. Likewise, compound analogs selected based on GPR139 agonist and antagonist substructure searches behaved similarly to their parent compounds. Thus, we have characterized GPR139 signaling for multiple new ligands using G protein-dependent assays and a new real-time internalization assay. These data add to the GPR139 tool compound repertoire, which could be optimized in future medical chemistry campaigns.

AB - The orphan G protein-coupled receptor GPR139 is predominantly expressed in the central nervous system and has attracted considerable interest as a therapeutic target. However, the biological role of this receptor remains somewhat elusive, in part due to the lack of quality pharmacological tools to investigate GPR139 function. In an effort to understand GPR139 signaling and to identify improved compounds, in this study we performed virtual screening and analog searches, in combination with multiple pharmacological assays. We characterized GPR139-dependent signaling using previously published reference agonists in Ca 2+ mobilization and inositol monophosphate accumulation assays, as well as a novel real-time GPR139 internalization assay. For the four reference agonists tested, the rank order of potency was conserved across signaling and internalization assays: JNJ-63533054 > Compound 1a » Takeda > AC4 > DL43, consistent with previously reported values. We noted an increased efficacy of JNJ-63533054-mediated inositol monophosphate signaling and internalization, relative to Compound 1a. We then performed virtual screening for GPR139 agonist and antagonist compounds that were screened and validated in GPR139 functional assays. We identified four GPR139 agonists that were active in all assays, with similar or reduced potency relative to known compounds. Likewise, compound analogs selected based on GPR139 agonist and antagonist substructure searches behaved similarly to their parent compounds. Thus, we have characterized GPR139 signaling for multiple new ligands using G protein-dependent assays and a new real-time internalization assay. These data add to the GPR139 tool compound repertoire, which could be optimized in future medical chemistry campaigns.

U2 - 10.1016/j.ejphar.2023.175553

DO - 10.1016/j.ejphar.2023.175553

M3 - Journal article

C2 - 36736525

VL - 943

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

M1 - 175553

ER -

ID: 335272382